Digital health company Adherium(ASX:ADR) has appointed Dr Peter Stratford as its CEO and Mike Motion at its Chief Commercial Officer (CCO).
The company said the appointments mean interim CEO Jeremy Curnock Cook and interim CCO Bill Hunter have relinquished their roles but both remain as Non-executive Directors on the Adherium board.
The company said Dr Stratford has over 30 years of experience in the pharmaceutical and medical device industries where he has led emerging and established medical device growth companies.
Most recently, Dr Stratford was Head of Innovation at BTG, which he joined in January 2011 following the acquisition of Biocompatibles International.
Dr Stratford joined Biocompatibles in 1990 and was appointed to the Board in 2002. He took the role of Group Director Research and Development in 1998 and moved to Oncology Products and Creation as part of the Interventional Oncology business. A
s Managing Director at Biocompatibles he was responsible for all aspects of development, manufacturing, regulatory and quality, working with the direct sales force and distributors in EMEA, APAC, China and Japan.
At BTG he was a part of the executive leadership team managing innovation across the vascular, oncology and respiratory portfolio and was instrumental in the acquisition and integration of the key businesses in each portfolio. Dr Stratford has a BSc in Chemistry, an MSc in Polymer Synthesis and a PhD in Pharmaceutical Synthesis.
Mr Motion has over 35 years of corporate experience in medical devices and pharmaceuticals starting his commercial career at Baxter Healthcare in 1984, working in manufacturing, sales and marketing and commercial leadership roles at UK, European and global levels.
Mr Motion joined Biocompatibles in 2005 to lead the commercialisation of its Interventional Oncology portfolio, setting up a direct sales force in the US and a global network of distributors in EMEA, APAC, China and Japan.
At BTG, Mr Motion held senior leadership roles as General Manager for Interventional Oncology and Head of Digital Innovation, developing and executing BTG’s digital health strategy in the therapeutic areas of oncology, anti-venom, vascular disease and respiratory.
“The appointments of Peter and Mike are a key step and an important phase of Adherium’s global business growth and commercialisation. This transition of control at the top of the company is a very considered step by the board,” said Mr Curnock Cook.
“This is new and top calibre experience to lead the company into its commercial growth phase to strive to deliver the promise of this technology. We welcome them to our team. Their experience with product commercialisation combined with our award-winning Hailie® products and technology platform will position Adherium to grow as a market leader in digital health.”
New CEO Dr Stratford said, "Adherium has some of the best technology in this space and our goal is to bring this to a successful commercial position. I look forward to leading the organisation to bring the benefits of the Hailie® solution to patients.”